BioMarin Pharmaceutical Inc [BMRN]
$83.99 1.04 (1.25%)
Market Cap 14.85 Billion
BioMarin's focus is on rare-disease therapies. Genzyme (now part of Sanofi) markets Aldurazyme through its joint venture with BioMarin, and BioMarin markets Naglazyme, Vimizim, and Brineura independently. BioMarin also markets Kuvan and Palynziq to treat the rare metabolic disorder PKU (in addition to long-standing U.S. rights, BioMarin has reacquired international rights for Kuvan and Palynziq from Merck KGaA). BioMarin has a hemophilia A gene therapy and a treatment for achondroplasia in late-stage clinical trials.
EPS -0.32 P/E Ratio 0.00
Previous Earnings Thu, Feb 21, 2019
Pay Date --
|Symbol||Price||Day %||YTD %|
This list of trending stocks may change throughout the trading day.